SCHEMBL7693227

SCHEMBL7693227

CCC=Cc1cccc2c1C(=O)NC2=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 4/20 0.42
GAA P10253 2/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 2/20 0.42
GSK3B P49841 3/20 0.39
PARP1 P09874 5/20 0.38
CASP3 P42574 6/20 0.37
CASP7 P55210 2/20 0.35
CASP2 P42575 1/20 0.35
CASP6 P55212 1/20 0.35
CASP8 Q14790 1/20 0.35
GSK3A P49840 1/20 0.35
CDK5 Q00535 1/20 0.35
CDK5R1 Q15078 1/20 0.35
RXFP1 Q9HBX9 1/20 0.34
MEN1 O00255 2/20 0.33
POLB P06746 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPK10 P53779 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7552794 1.00 KDM4E (0.42) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL8577337 0.81 KDM4E (0.45) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL1627401 0.75 GSK3B (0.48) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL31229225 0.75 GSK3B (0.48) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL6413053 0.75 ALDH1A1 (0.41) KDM4EALDH1A1CYP1A2TDP1SLC37A4
SCHEMBL6413047 0.75 ALDH1A1 (0.41) KDM4EALDH1A1CYP1A2TDP1SLC37A4
SCHEMBL28735098 0.75 GSK3B (0.41) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL9333299 0.75 KDM4E (0.47) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL626418 0.74 GSK3B (0.46) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL579203 0.74 GSK3B (0.46) KDM4EALDH1A1GAAHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102264733-A novel dopamine D3 receptor ligand, preparation method and medical application thereof 2011-11-30 CN disclosed
US-6337351-B1 AROMATIC OLEFIN AMINES TARGACEPT, INC. 2002-01-08 US disclosed
US-6310102-B1 OXY OR HYDROXY OR NITRO SUBSTITUTED PHENYLALKYLENE AMINE DERIVATIVE USED FOR TREATING A CENTRAL NERVOUS SYSTEM DISORDER CHARACTERIZED BY AN ALTERATION IN NORMAL NEUROTRANSMITTER RELEASE TARGACEPT, INC. 2001-10-30 US disclosed
US-6262124-B1 FOR ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS, FOR EXAMPLE, AS AGONISTS OF SPECIFIC NICOTINIC RECEPTOR SUBTYPES; FOR THERAPY OF DYSFUNCTION OF THE CENTRAL AND AUTONOMIC NERVOUS SYSTEMS TARGACEPT, INC., A CORPORATION OF DELAWARE 2001-07-17 US disclosed
EP-1042274-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE R.J. REYNOLDS TOBACCO COMPANY (US) 2000-10-11 EP disclosed
WO-2000023418-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE R.J. REYNOLDS TOBACCO COMPANY (US) 2000-04-27 WO disclosed